医师专科在转移性去势敏感性前列腺癌患者标准治疗强化利用不足中的作用
该回顾性研究利用Optum研究数据库2014至2019年数据,分析4675例转移性去势敏感性前列腺癌患者接受雄激素剥夺治疗强化的医师专科差异。结果显示一线治疗强化在肿瘤科或两科共管患者中不足40%,仅泌尿外科医生处不足15%;后续治疗线中雄激素剥夺治疗联合雄激素受体通路抑制剂在各专科均超过50%。作者认为需更早进行强化治疗。
要点
- 4675例患者中,仅泌尿外科医生治疗者占16%,仅肿瘤科医生占20%,两科共管占63%,其他专科占1.1%。
- 一线治疗以雄激素剥夺治疗±第一代非甾体抗雄激素为主(>50%),雄激素剥夺治疗联合多西他赛使用随时间下降,联合雄激素受体通路抑制剂使用增加。
- 截至2019年,仅肿瘤科医生或两科共管者一线强化治疗仍<40%,仅泌尿外科医生者<15%。
核心结论
- 尽管有生存获益证据,一线治疗强化在泌尿外科和肿瘤科专科中均利用不足。
- 后续治疗线中,雄激素剥夺治疗联合雄激素受体通路抑制剂在各专科中处方更频繁。
- 作者认为这些结果强调泌尿外科医生和肿瘤科医生需要更早进行治疗强化。
研究设计与样本
- 回顾性研究,利用Optum研究数据库2014至2019年数据,纳入接受雄激素剥夺治疗的成人转移性去势敏感性前列腺癌男性患者。
- 共纳入4675例患者,医师专科根据每线治疗期间的医疗/药房索赔分为仅泌尿外科医生、仅肿瘤科医生、两者兼有或其他专科。
- 治疗强化和患者特征进行描述性分析。
主要发现
- 4675例患者中,16%仅由泌尿外科医生治疗,20%仅由肿瘤科医生治疗,63%由两者共同治疗,1.1%由其他专科治疗。
- 最常见的一线治疗为雄激素剥夺治疗±第一代非甾体抗雄激素(>50%);雄激素剥夺治疗联合多西他赛使用随时间下降,而联合雄激素受体通路抑制剂使用增加。
- 由肿瘤科医生或两者共同治疗的患者更年轻、合并症更少,且相比仅由泌尿外科医生治疗者更可能接受治疗强化。
- 截至2019年,仅肿瘤科医生或两者共同治疗者中治疗强化仍<40%,仅泌尿外科医生治疗者中<15%。
- 在第二和第三线治疗中,雄激素剥夺治疗联合雄激素受体通路抑制剂是各专科最常处方的方案(>50%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluate utilization of treatment intensification of androgen deprivation therapy with androgen receptor pathway inhibitor/docetaxel for metastatic castration-sensitive prostate cancer patients across physician specialties. MATERIALS AND METHODS: This retrospective study identified patients with metastatic castration-sensitive prostate cancer in the Optum Research Database between 2014 and 2019. Adult men with ≥1 claim for metastatic disease within 90 days before or any time after the first prostate cancer claim who received androgen deprivation therapy were included. Physician specialty, determined from medical/pharmacy claims during each line of therapy, was categorized as urologist only, oncologist only, both (urologists and oncologists), or other (other specialties). Treatment intensification and patient characteristics were analyzed descriptively. RESULTS: Of 4,675 patients, 16% were treated by urologists only, 20% by oncologists only, 63% by both, and 1.1% by others. The most frequent first line of therapy was androgen deprivation therapy ± first-generation nonsteroidal antiandrogens (>50%). Androgen deprivation therapy + docetaxel use declined over time, while androgen deprivation therapy + androgen receptor pathway inhibitor use increased. Patients seen by oncologists or both were younger, had fewer comorbidities, and were likelier to receive treatment intensification compared to those treated by urologists. By 2019, however, treatment intensification remained <40% from oncologists only or both, and <15% from urologists only. In the second and third lines of therapy, androgen deprivation therapy + androgen receptor pathway inhibitor was the most prescribed regimen across specialties (>50%). CONCLUSIONS: Treatment intensification was underused in first lines of therapy across urology and oncology specialties despite evidence of improved survival. In subsequent lines, androgen deprivation therapy + androgen receptor pathway inhibitor was prescribed more frequently across specialties. These results underscore the need for earlier treatment intensification by urologists and oncologists.
引用
- Swami U, Hong A, El-Chaar NN, et al. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer. J Urol. 2023. PMID: 36789668. doi:10.1097/JU.0000000000003370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。